malignancy

(redirected from malignancies)
Also found in: Thesaurus, Medical, Encyclopedia.

ma·lig·nan·cy

 (mə-lĭg′nən-sē)
n. pl. ma·lig·nan·cies
1. also ma·lig·nance (-nəns) The state or quality of being malignant.
2. A malignant tumor.

malignancy

(məˈlɪɡnənsɪ)
n, pl -cies
1. the state or quality of being malignant
2. (Pathology) pathol a cancerous growth

ma•lig•nan•cy

(məˈlɪg nən si)

n., pl. -cies.
1. the quality or condition of being malignant.
2. malignant character or behavior.
3. a malignant tumor.
Also, ma•lig′nance (for defs. 1, 2).
[1595–1605]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.malignancy - (medicine) a malignant statemalignancy - (medicine) a malignant state; progressive and resistant to treatment and tending to cause death
cancer cell - a cell that is part of a malignant tumor
medical specialty, medicine - the branches of medical science that deal with nonsurgical techniques
malignant neoplasm, malignant tumor, metastatic tumor - a tumor that is malignant and tends to spread to other parts of the body
2.malignancy - quality of being disposed to evilmalignancy - quality of being disposed to evil; intense ill will
evilness, evil - the quality of being morally wrong in principle or practice; "attempts to explain the origin of evil in the world"
benignancy, benignity, graciousness - the quality of being kind and gentle

malignancy

noun
Translations

malignancy

[məˈlɪgnənsɪ] Nmalignidad f

malignancy

[məˈlɪgnənsi] n [tumour, disease] → malignité f

malignancy

nBösartigkeit f; (Med) → Malignität f (spec), → Bösartigkeit f; (fig: = evil thing) → Übel nt

malignancy

[məˈlɪgnənsɪ] n (of person, remark) → malignità f inv; (of tumour) → carattere m maligno

ma·lig·nan·cy

1. n. cualidad de malignidad;
2. tumor canceroso.

malignancy

n malignidad f, cáncer m
References in periodicals archive ?
8, 2019 (HealthDay News) -- First-degree relatives of patients with hematological malignancies have increased relative risks for the same tumor types and some different hematological malignancies, according to a study published online Aug.
The study of 993 patients with 245 malignancies shows that Verm's second generation multivariate index assay, Overa (MIA2G), had superior sensitivity to the current standards of care, Risk of Malignancy Algorithm and CA125, in detecting ovarian cancer, and the lowest false-negative rate in correctly characterizing ovarian malignancy risk.
The study of 993 patients with 245 malignancies shows that Vermillion's second generation multivariate index assay, Overa, had superior sensitivity to the current standards of care, Risk of Malignancy Algorithm, or ROMA, and CA125, in detecting ovarian cancer, and the lowest false-negative rate in correctly characterizing ovarian malignancy risk.
-- A retrospective study suggests patients with mycosis fungoides have an increased risk of developing hematologic and solid-tumor malignancies.
There is a complex relationship between malignancies and rheumatic diseases.
Skin malignancies are predominantly an ultra-violet (UV) light induced skin cancers, more commonly occurring in light skinned Caucasians than in individuals with darker skin1.
Biopharmaceutical company Innovent Biologics Inc (HKEX:01801) reported on Monday that it has started treatment of the first patient under its phase I clinical trial of anti-CD47 monoclonal antibody (IBI188) for patients with advanced malignancies in China.
The Qatar Cancer Society (QCS) held a symposium on the 'Haematological Malignancies For Primary Care' in co-operation with National Centre for Cancer Care & Research at Ooredoo Cancer Awareness Centre recently.
The second primary malignancies are not uncommon and, nowadays, the prevalence of it is mildly increasing due to the increasing survival of cancer patients and advances in early diagnosis and therapeutic modalities.
Similarly, the cancer data in children shows hematolymphoid malignancies like leukaemia and lymphomas as the leading cancer followed by brain and bone malignancies.
The short-term results of this series showed that 100% of all malignancies were Fuhrman G1/2 and no development of metastatic disease during the 3 year period of follow-up in this study.
Cutaneous Malignancies: A Surgical Perspective (online access included)